Scholars@Duke
Jerrold Henry Levy

Jerrold Henry Levy

Professor Emeritus of Anesthesiology
Anesthesiology, Cardiothoracic

Scholarly Works - Other

In Response.

Other Anesth Analg · May 2020 Full text Link to item Cite

Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.

Other Am J Med · November 2016 Patients taking direct oral anticoagulants (DOACs) who then need an emergency invasive procedure require specialized management strategies. Appropriate patient evaluation includes assessment of the current anticoagulation state, including timing of the las ... Full text Link to item Cite

Antithrombin: anti-inflammatory properties and clinical applications.

Other Thromb Haemost · April 2016 Many humoral and cellular components participate in bidirectional communication between the coagulation and inflammation pathways. Natural anticoagulant proteins, including antithrombin (AT), tissue factor pathway inhibitor, and protein C, suppress proinfl ... Full text Link to item Cite

The Judicious Use of Recombinant Factor VIIa.

Other Semin Thromb Hemost · March 2016 Recombinant activated factor VIIa (rFVIIa) is a prohemostatic agent initially approved for use in hemophilia patients with inhibitors and recently for Glanzmann thrombasthenia. Despite its approval indications, rFVIIa has also been used for a diverse range ... Full text Link to item Cite

Edoxaban in the secondary prevention of VTE

Other Lancet Haematology · March 2016 Cite

Novel oral anticoagulants and reversal agents: Considerations for clinical development.

Other Am Heart J · June 2015 This white paper provides a summary of presentations and discussions that were held at an Anticoagulant-Induced Bleeding and Reversal Agents Think Tank co-sponsored by the Cardiac Safety Research Consortium and the US Food and Drug Administration (FDA) at ... Full text Link to item Cite

Anticoagulation management associated with extracorporeal circulation.

Other Best Pract Res Clin Anaesthesiol · June 2015 The use of extracorporeal circulation requires anticoagulation to maintain blood fluidity throughout the circuit, and to prevent thrombotic complications. Additionally, adequate suppression of hemostatic activation avoids the unnecessary consumption of coa ... Full text Link to item Cite

Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.

Other Crit Care · April 29, 2015 Perioperative management of patients treated with the non-vitamin K antagonist oral anticoagulants is an ongoing challenge. Due to the lack of good clinical studies involving adequate monitoring and reversal therapies, management requires knowledge and und ... Full text Link to item Cite

Point of care and factor concentrate-based coagulation algorithms.

Other Transfus Med Hemother · March 2015 In the last years it has become evident that the use of blood products should be reduced whenever possible. There is increasing evidence regarding serious adverse events, including higher mortality and morbidity, related to transfusions. The use of point o ... Full text Link to item Cite

How I use fibrinogen replacement therapy in acquired bleeding.

Other Blood · February 26, 2015 Fibrinogen is a critical protein for hemostasis and clot formation. However, transfusion guidelines have variable recommendations for maintaining fibrinogen levels in bleeding patients. An increasing number of studies support the practice of fibrinogen rep ... Full text Link to item Cite

Cryoprecipitate therapy.

Other Br J Anaesth · December 2014 Cryoprecipitate, originally developed as a therapy for patients with antihaemophilic factor deficiency, or haemophilia A, has been in use for almost 50 yr. However, cryoprecipitate is no longer administered according to its original purpose, and is now mos ... Full text Link to item Cite

Direct oral anticoagulants: new drugs and new concepts.

Other JACC Cardiovasc Interv · December 2014 Direct oral anticoagulants (DOACs) are approved for multiple thromboembolic disorders and provide advantages over existing agents. As with all anticoagulants, management protocols for the eventuality of bleeding are important. Randomized phase III studies ... Full text Link to item Cite

Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.

Other Clin Lab Med · September 2014 New oral anticoagulants (NOACs) are increasingly replacing vitamin K antagonists and older parenteral agents in clinical practice. NOACs offer several advantages compared with standard agents, including rapid onset of action, fixed dosing, and no requireme ... Full text Link to item Cite

Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing.

Other Clin Lab Med · September 2014 Although the activated partial thromboplastin time, prothrombin time, and international normalized ratio are widely used in routine preoperative testing, these hemostatic tests are not reliable predictors of perioperative bleeding in patients without known ... Full text Link to item Cite

Anticoagulation strategies for the management of postoperative atrial fibrillation.

Other Clin Lab Med · September 2014 Patients undergoing thoracic and cardiac procedures are at the highest risk for postoperative atrial fibrillation (POAF). POAF is associated with poor short-term and long-term outcomes, including high rates of early and late stroke, and late mortality. Pat ... Full text Link to item Cite

New oral anticoagulant-induced bleeding: clinical presentation and management.

Other Clin Lab Med · September 2014 Bleeding is a significant complication of anticoagulant therapy. With the emergence of new oral anticoagulants (NOACs; ie, direct factor IIa or Xa inhibitors), this risk is further compounded by the lack of validated reversal strategies for these agents. E ... Full text Link to item Cite

Off-label use of recombinant human factor VIIa

Other The Annals of Thoracic Surgery · August 2014 Invited commentary ... Cite

Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.

Other Transfusion · May 2014 Fibrinogen plays a critical role in achieving and maintaining hemostasis and is fundamental to effective clot formation. There is increasing awareness of the important role of fibrinogen as a key target for the treatment and prevention of acquired bleeding ... Full text Link to item Cite

Managing new oral anticoagulants in the perioperative and intensive care unit setting.

Other Anesthesiology · June 2013 Managing patients in the perioperative setting receiving novel oral anticoagulation agents for thromboprophylaxis or stroke prevention with atrial fibrillation is an important consideration for clinicians. The novel oral anticoagulation agents include dire ... Full text Link to item Cite

Concepts of blood transfusion in adults.

Other Lancet · May 25, 2013 Recent progress has been made in the identification and implementation of best transfusion practices on the basis of evidence-based clinical trials, published clinical practice guidelines, and process improvements for blood use and clinical patient outcome ... Full text Link to item Cite

Biology of Factor XIII and clinical manifestations of Factor XIII deficiency.

Other Transfusion · May 2013 Factor XIII (FXIII) is activated by thrombin to form a transglutaminase (FXIIIa) that stabilizes clot formation by the cross-linking of fibrin monomers and antifibrinolytic proteins. Although rare, FXIII deficiency is characterized by variable bleeding man ... Full text Link to item Cite

Point of care devices for assessing bleeding and coagulation in the trauma patient.

Other Anesthesiol Clin · March 2013 Severe trauma is associated with bleeding, coagulopathy, and transfusion of blood and blood products, all contributing to higher rates of morbidity and mortality. The aim of this review is to focus on point-of-care devices to monitor coagulation in trauma. ... Full text Link to item Cite

Perioperative coagulation management in the intensive care unit.

Other Curr Opin Anaesthesiol · February 2013 PURPOSE OF REVIEW: Coagulopathy in an ICU setting is multifactorial, but newer anticoagulation agents are the potentially contributing causes. Critically ill patients may suffer from disorders because of surgery or trauma, in addition to acquired causes in ... Full text Link to item Cite

Complement activation and cardiac surgery: a novel target for improving outcomes.

Other Anesth Analg · October 2012 Complement activation and the resulting inflammatory response is an important potential mechanism for multisystem organ injury in cardiac surgery. Novel therapeutic strategies using complement inhibitors may hold promise for improving outcomes for cardiac ... Full text Link to item Cite

Hemoglobin drift after cardiac surgery

Other The Annals of Thoracic Surgery · September 2012 Invited commentary ... Cite

Prohemostatic treatment in cardiac surgery.

Other Semin Thromb Hemost · April 2012 Cardiac surgical patients represent a unique group of patients where coagulopathy occurs due to multiple causes besides simple hemorrhagic blood loss. Hemodilution, inflammation, and hemostatic activation while on cardiopulmonary bypass all contribute to t ... Full text Link to item Cite

Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding.

Other Anesth Analg · February 2012 Fibrinogen plays several key roles in the maintenance of hemostasis. Its cleavage by thrombin and subsequent polymerization to form fibrin strands provides the structural network required for effective clot formation. During cases of acute blood loss, atte ... Full text Link to item Cite

Managing clotting: a North American perspective.

Other Curr Opin Anaesthesiol · February 2012 PURPOSE OF REVIEW: Bleeding in a perioperative setting occurs due to multiple causes, but newer anticoagulant and antiplatelet therapies are increasingly used preoperatively. As a result, patients often can present for surgery with underlying hemostatic di ... Full text Link to item Cite

A hemorrhage of off-label use

Other Annals of Internal Medicine · September 2011 Cite

Bleeding and management of coagulopathy.

Other J Thorac Cardiovasc Surg · September 2011 Bleeding after cardiac surgery remains a significant problem, increasing both length of stay and mortality, and is caused by multiple factors including dilutional changes, ongoing fibrinolysis, and platelet dysfunction. The evaluation of coagulopathy is pr ... Full text Link to item Cite

Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia.

Other Anesth Analg · January 2011 Hypercoagulability, or thrombophilia, is a condition associated with an abnormally increased tendency toward blood clotting. Affected individuals are prone to developing venous or arterial thrombosis and often require thromboprophylaxis. Hypercoagulability ... Full text Link to item Cite

Novel oral anticoagulants: implications in the perioperative setting.

Other Anesthesiology · September 2010 Patients undergoing surgery receive anticoagulation for perioperative thromboprophylaxis or ischemic cardiovascular disease. Because anticoagulants may also potentiate bleeding, clinicians need to understand the implications of anticoagulation in periopera ... Full text Link to item Cite

Hereditary angioedema: current and emerging treatment options.

Other Anesth Analg · May 1, 2010 Angioedema can result from allergic, hereditary, and acquired conditions. Hereditary angioedema (HAE) attacks are disabling at the time of occurrence and can be life threatening; they often result in hospitalization and intensive care unit admission. Altho ... Full text Link to item Cite

Multidisciplinary approach to the challenge of hemostasis.

Other Anesth Analg · February 1, 2010 A multidisciplinary panel consisting of experts chosen by the 2 chairs of the group representing experts in anesthesiology, blood banking, hematology, critical care medicine, and various surgical disciplines (trauma, cardiac, pediatric, neurologic, obstetr ... Full text Link to item Cite

Heparin-induced thrombocytopenia and cardiac surgery.

Other Curr Opin Anaesthesiol · February 2010 PURPOSE OF REVIEW: Heparin-induced thrombocytopenia (HIT) is an important, increasingly recognized antibody-mediated complication of heparin therapy occurring in approximately 0.5-5% of patients receiving heparin for at least 5 days. HIT is a prothrombotic ... Full text Link to item Cite

Blood coagulation: hemostasis and thrombin regulation.

Other Anesth Analg · May 2009 Perioperative bleeding is a major challenge particularly because of increasing clinical use of potent antithrombotic drugs. Understanding current concepts of coagulation is important in determining the preoperative bleeding risk of patients, and in managin ... Full text Link to item Cite

Perioperative hemostatic management of patients treated with vitamin K antagonists.

Other Anesthesiology · November 2008 Clinicians, including anesthesiologists, surgeons, and intensivists, are frequently called on to correct coagulopathy in patients receiving oral anticoagulation therapy. Before elective surgery, anticoagulation reversal may be undertaken over several days ... Full text Link to item Cite

Prohemostatic agents to prevent perioperative blood loss.

Other Semin Thromb Hemost · July 2008 Surgical patients represent a unique group of patients where therapeutic approaches can be preemptively administered. Pharmacologic strategies to prevent or decrease perioperative bleeding function to attenuate inflammatory responses, reduce hemostatic act ... Full text Link to item Cite

Anaphylaxis during cardiac surgery: implications for clinicians.

Other Anesth Analg · February 2008 During surgery, patients are exposed to multiple foreign substances including anesthetic drugs, antibiotics, blood products, heparin, polypeptides (aprotinin, latex, and protamine), and intravascular volume expanders, which have the potential to produce li ... Full text Link to item Cite

The anticoagulated patient: strategies for effective blood loss management.

Other Surgery · October 2007 Anticoagulant therapy is challenging to modern surgical practice because it complicates risks of bleeding and the need for allogeneic blood transfusions. In an aging population, there is extensive use of antiplatelet agents, and patients present for operat ... Full text Link to item Cite

Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia.

Other Anesth Analg · September 2007 Heparins are widely used in the perioperative setting. Immune heparin-induced thrombocytopenia (HIT) is a serious, antibody-mediated complication of heparin therapy that occurs in approximately 0.5%-5% of patients treated with heparin for at least 5 days. ... Full text Link to item Cite

Heparin resistance and the potential impact on maintenance of therapeutic coagulation

Other European Journal of Anaesthesiology · June 1, 2007 Background and objectives: The main aim of this review is to summarize the literature with respect to the impact of anticoagulation monitoring strategies and therapeutic strategies to manage heparin resistance and optimize anticoagulation with cardiac surg ... Full text Cite

Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas.

Other Hematol Oncol Clin North Am · February 2007 Hemostatic abnormalities occur following injury associated with both cardiac and noncardiac surgery. These changes are part of inflammatory pathways with signaling mechanisms that link these diverse pathways. The inflammatory response to surgery is exacerb ... Full text Link to item Cite

Heparin-induced thrombocytopenia, a prothrombotic disease.

Other Hematol Oncol Clin North Am · February 2007 Heparin-induced thrombocytopenia (HIT) is a serious, yet treatable prothrombotic disease that develops in approximately 0.5% to 5% of heparin-treated patients and dramatically increases their risk of thrombosis (odds ratio, 37). The antibodies that mediate ... Full text Link to item Cite

Regulation of thrombin activity--pharmacologic and structural aspects.

Other Hematol Oncol Clin North Am · February 2007 Thrombin is an essential serine protease for survival. Since the discovery of heparin in the early twentieth century, significant advances have been made in the understanding of thrombin structure and function in coagulation system. Endogenous anticoagulan ... Full text Link to item Cite

Use of aprotinin in extrapleural pneumonectomy: effect on hemostasis and incidence of complications

Other The Annals of Thoracic Surgery · 2007 Invited commentary ... Cite

The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema.

Other Expert Opin Investig Drugs · September 2006 Hereditary angioedema (HAE) manifests as intermittent, painful attacks of submucosal oedema affecting the larynx, gastrointestinal tract or limbs. Currently, acute treatment is available in Europe but not USA, and requires intravenous administration of a p ... Full text Link to item Cite

To the editor [9]

Other New England Journal of Medicine · June 19, 2006 Cite

Aprotinin in cardiac surgery

Other The New England journal of medicine · 2006 Cite

Aprotinin is useful as a hemostatic agent in cardiac surgery

Other Journal of Thrombosis and Haemostasis · 2006 Invited commentary ... Cite

Massive transfusion coagulopathy.

Other Semin Hematol · January 2006 Coagulopathy following massive transfusion is a consequence of post-traumatic and surgical hemorrhage. Bleeding following massive transfusion can occur due to hypothermia, dilutional coagulopathy, platelet dysfunction, fibrinolysis, or hypofibrinogenemia. ... Full text Link to item Cite

Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation.

Other Am J Health Syst Pharm · September 15, 2005 PURPOSE: The pharmacologic management of hemostasis in patients undergoing surgery with cardiopulmonary bypass is discussed. SUMMARY: Nearly 45 studies involving 7,000 patients have reported efficacy of aprotinin in blood conservation. Both in primary coro ... Full text Link to item Cite

Evaluation and management of bleeding during cardiac surgery.

Other Curr Hematol Rep · September 2005 Patients undergoing cardiac surgery with and potentially without cardiopulmonary bypass (CPB) are at risk for excessive microvascular bleeding. This bleeding often leads to transfusion of allogeneic blood and blood components as well as reexploration. Exce ... Link to item Cite

Activated recombinant factor VII in cardiac surgery.

Other Curr Opin Anaesthesiol · February 2005 PURPOSE OF REVIEW: Severe bleeding after cardiac surgery is a potential problem that poses major risks and challenges. Severe bleeding after cardiac surgery still occurs despite many pharmacological approaches to decrease bleeding and reduce transfusion re ... Full text Link to item Cite

Management of systemic and pulmonary hypertension.

Other Tex Heart Inst J · 2005 The major therapeutic approach to systemic and pulmonary hypertension and vasospasm in cardiac surgery patients involves the use of parenteral agents that reverse systemic vasoconstriction and produce vasodilation. Potential pharmacologic approaches includ ... Link to item Cite

Aprotinin: a pharmacologic overview.

Other Orthopedics · June 2004 Aprotinin is a polypeptide with serine protease inhibitory activity of key enzymes associated with inflammatory, fibrinolytic, and hemostatic pathways. The drug binds directly to the fibrinolytic plasmin at the lower plasmin-inhibiting dose (plasma concent ... Full text Link to item Cite

Efficacy and safety of aprotinin in cardiac surgery.

Other Orthopedics · June 2004 Cardiac surgery and cardiopulmonary bypass produces bleeding and the need for allogenic blood product transfusions in many patients. Blood conservation is important in the perioperative management of patients. Aprotinin, a serine protease inhibitor isolate ... Full text Link to item Cite

Hemostatic agents

Other Transfusion · 2004 Cite

Heparin resistance and antithrombin: Can we stop calling it heparin resistance?

Other Journal of Cardiothoracic and Vascular Anesthesia · 2004 Cite

The use of haemoglobin glutamer-250 (HBOC-201) as an oxygen bridge in patients with acute anaemia associated with surgical blood loss.

Other Expert Opin Biol Ther · June 2003 For the treatment of substantial blood loss in surgery, allogeneic blood is transfused to maintain stability and organ perfusion and function. Continued concerns about the availability, safety, efficacy and storage-related problems of allogeneic blood prod ... Full text Link to item Cite

Inflammatory response to cardiopulmonary bypass.

Other Ann Thorac Surg · February 2003 Inflammation in cardiac surgical patients is produced by complex humoral and cellular interactions with numerous pathways including activation, generation, or expression of thrombin, complement, cytokines, neutrophils, adhesion molecules, mast cells, and m ... Full text Link to item Cite

Novel pharmacologic approaches to reducing bleeding

Other Canadian Journal of Anesthesia / Journal canadien d'anesthésie · 2003 Cite

Stroke after cardiac surgery: a retrospective analysis of the effect of aprotinin dosing regimens

Other The Annals of Thoracic Surgery · 2003 Invited commentary ... Cite

Intravenous milrinone in cardiac surgery.

Other Ann Thorac Surg · January 2002 Phosphodiesterase inhibitors including milrinone produce positive inotropic effects by slowing the hydrolysis of cyclic adenosine monophosphate in the myocardium. With a loading dose of 50 microg/kg followed by an infusion of 0.5 microg x kg(-1) x min(-1), ... Full text Link to item Cite

Anaphylaxis. What is monitored to make a diagnosis? How is therapy monitored?

Other Anesthesiol Clin North Am · December 2001 Anaphylaxis is one of the most life-threatening emergencies that can occur in the perioperative period. Multiple agents can be responsible, and nonallergic reactions can mimic anaphylaxis. Developing a therapeutic plan for the acute therapy of anaphylaxis ... Link to item Cite

Pharmacologic preservation of the hemostatic system during cardiac surgery.

Other Ann Thorac Surg · November 2001 Bleeding after cardiac surgery remains a major potential problem. Numerous pharmacologic approaches to attenuating hemostatic system activation in cardiac surgery patients have been studied to further improve patient management. Therapeutic approaches stud ... Full text Link to item Cite

Recombinant antithrombin, production: role in cardiovascular disorders

Other Seminars in Thrombosis and Hemostasis · 2001 Cite

Anaphylactic reactions during cardiac surgery: Et tu brute?

Other Journal of Cardiothoracic and Vascular Anesthesia · 2001 Cite

Platelet inhibitors and bleeding in cardiac surgical patients.

Other Ann Thorac Surg · August 2000 A variety of measures may affect bleeding and transfusion requirements in abciximab-treated patients. These measures include recognition of the risk factors for increased bleeding and transfusion requirements, use of proper transfusion practices, conservat ... Full text Link to item Cite

Fast tracking for cardiovascular surgery

Other Seminars in Anesthesia, Perioperative Medicine and Pain · 2000 Cite

Cardiovascular safety issues and the use of neuromuscular blocking agents

Other Seminars in Anesthesia, Perioperative Medicine and Pain · 2000 Cite

Management strategies for high-risk cardiac surgery: improving outcomes in patients with heart failure.

Other Heart Surg Forum · 2000 BACKGROUND: Surgical heart failure management is the fastest growing aspect of cardio-vascular surgery. Advances in cardiac surgical techniques have changed the number and types of operations permitted physicians and thus broadened the complexity of patien ... Link to item Cite

Hemostatic agents and their safety.

Other J Cardiothorac Vasc Anesth · August 1999 The pharmacologic management of hemostasis in patients undergoing cardiopulmonary bypass may be accompanied by adverse responses. Evaluating the safety profile of hemostatic agents (eg, lysine analogs, aprotinin, protamine, or even donor blood) should be d ... Link to item Cite

Fenoldopam: a new parenteral antihypertensive: consensus roundtable on the management of perioperative hypertension and hypertensive crises.

Other Am J Hypertens · July 1999 A panel of clinicians from anesthesiology, surgery, nephrology, hypertension, cardiology, and pharmacology was convened to discuss pharmacologic therapeutics in the management of hypertensive crisis and perioperative hypertension. The panel discussed the a ... Full text Link to item Cite

Anaphylactic reactions in anesthesia and intensive care

Other Acta Anaesthesiologica Scandinavica · 1999 Cite

Treatment of perioperative hypertension

Other Anesthesiology Clinics of North America · January 1, 1999 Perioperative hypertension during cardiac or noncardiac surgery is a unique clinical problem characterized by systemic vasoconstriction often with intravascular hypovolemia that usually requires acute short-term intravenous therapy. β-Adrenergic blockers a ... Full text Cite

Anaphylactic emergencies

Other Seminars in Anesthesia · January 1, 1998 Anaphylaxis represents one of the most life-threatening emergencies that can occur in the perioperative period. Multiple agents are potentially responsible, and nonallergic reactions can mimic anaphylaxis. Developing a therapeutic plan for the acute therap ... Full text Cite

The inflammatory response to cardiopulmonary bypass.

Other J Cardiothorac Vasc Anesth · May 1997 The inflammatory response to cardiopulmonary bypass is the product of a complex interplay of humoral and cellular components. Contact activation cascades, the complement system, and cytokines comprise the humoral elements and interact in such a way as to p ... Full text Link to item Cite

ACT and antithrombin effects

Other Circulation · 1997 Cite

Anaphylaxis and coronary disease.

Other N Engl J Med · December 19, 1996 Link to item Cite

The human inflammatory response.

Other J Cardiovasc Pharmacol · 1996 Inflammation is a protective response of vascularized tissue normally elicited toward nonself-determinants or tissue injury. Inflammation functions as part of normal host surveillance mechanisms to destroy or quarantine both harmful agents and damaged tiss ... Full text Link to item Cite

Heparin neutralization by recombinant factor 4 and heparinase

Other Anaesthetic Pharmacology Review · 1995 Cite

Support of the perioperative failing heart with preexisting ventricular dysfunction: currently available options.

Other J Cardiothorac Vasc Anesth · August 1993 Perioperative support of the patient with preexisting biventricular failure requires simultaneous optimal manipulation of heart rate and rhythm, loading conditions, and contractility. Patients with preexisting ventricular dysfunction will have alterations ... Full text Link to item Cite

Adverse reactions to protamine.

Other Coron Artery Dis · May 1993 Full text Link to item Cite

New concepts in the treatment of anaphylactoid reactions in anaesthesia

Other Acta Anaesthesiologica Scandinavica · January 1, 1993 Full text Cite

Anaphylactic reaction to thiopental

Other Journal of the American Medical Association · January 1, 1993 Full text Cite

The ideal agent for perioperative hypertension and potential cytoprotective effects.

Other Acta Anaesthesiol Scand Suppl · 1993 Perioperative hypertension is primarily due to increased systemic vascular resistance (SVR). Therefore, the major therapeutic approaches are directed at reducing vasoconstriction, using drugs that increase cyclic nucleotides or block calcium entry into vas ... Full text Link to item Cite

Perioperative experience with amrinone.

Other Eur J Anaesthesiol Suppl · 1992 Amrinone is the only phosphodiesterase fraction III inhibitor currently available in the USA for the treatment of perioperative biventricular failure. Patients with chronic congestive heart failure (CHF) show down-regulation of the beta 1-adrenergic recept ... Link to item Cite

Aprotinin and its heparin-sparing effect

Other The Journal of Thoracic and Cardiovascular Surgery · 1991 Cite

Anaphylactic reactions during cardiac surgery

Other Perfusion · 1991 Anaphylactic reactions during cardiac surgery may present as acute cardiopulmonary dysfunction and require prompt and aggressive therapy. Recognition, with appropriate therapeutic intervention, is essential to prevent the life-threatening complications ass ... Cite

Pharmacokinetics and pharmacodynamics of phosphodiesterase-III inhibitors

Other Journal of Cardiothoracic Anesthesia · January 1, 1990 Full text Cite

Amrinone: pharmacokinetics and pharmacodynamics.

Other J Cardiothorac Anesth · December 1989 Amrinone is a selective inhibitor of phosphodiesterase fraction 3 in both cardiac and smooth muscle. Intravenous administration in humans produces increased contractility and vasodilation of venous capacitance and arterial conductance vessels. The eliminat ... Full text Link to item Cite

Allergic reactions during anesthesia.

Other J Clin Anesth · 1988 Any drug or blood product administered in the perioperative period has the potential to produce a life-threatening allergic (immune reaction) called anaphylaxis. Anaphylactic reactions represent adverse reactions mediated by immunospecific antibodies (IgE ... Full text Link to item Cite

Anaphylactic and anaphylactoid reactions. A review.

Other Spine (Phila Pa 1976) · April 1986 Anaphylaxis is a life-threatening, immunologically mediated reaction. "Anaphylactoid" reactions produce the same clinical syndrome but are not immunologically mediated. Vasoactive mediators of these reactions include histamine, eosinophilic chemotactic fac ... Full text Link to item Cite

Inadvertent transbronchial insertion of narrow-bore feeding tubes into the pleural space.

Other JAMA · May 11, 1984 Four patients had soft, narrow-bore feeding tubes passed transbronchially into the pleural space. Guide wires were used to aid passage and may have contributed to this complication. The errant positioning of the tube was first noted roentgenographically in ... Link to item Cite

Case Records of the Massachusetts General Hospital

Other The New England journal of medicine · 1983 Discussant in case 19-1983 ... Cite

Intravenous epinephrine therapy in anaphylaxis

Other Journal of the American Medical Association · 1983 Full text Cite

Anaphylaxis to meperidine.

Other Anesth Analg · March 1982 Link to item Cite